TLSI vs. SGHT, INO, ANGO, UTMD, NPCE, TMCI, GUTS, RCEL, TCMD, and PROF
Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include Sight Sciences (SGHT), Inovio Pharmaceuticals (INO), AngioDynamics (ANGO), Utah Medical Products (UTMD), NeuroPace (NPCE), Treace Medical Concepts (TMCI), Fractyl Health (GUTS), AVITA Medical (RCEL), Tactile Systems Technology (TCMD), and Profound Medical (PROF). These companies are all part of the "surgical & medical instruments" industry.
Sight Sciences (NASDAQ:SGHT) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 27.1% of Sight Sciences shares are owned by insiders. Comparatively, 76.2% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
TriSalus Life Sciences has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -67.18%. Sight Sciences' return on equity of 0.00% beat TriSalus Life Sciences' return on equity.
Sight Sciences presently has a consensus price target of $4.70, indicating a potential downside of 11.99%. TriSalus Life Sciences has a consensus price target of $16.00, indicating a potential upside of 62.44%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Sight Sciences.
Sight Sciences has higher revenue and earnings than TriSalus Life Sciences.
Sight Sciences received 14 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
Sight Sciences has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
In the previous week, TriSalus Life Sciences had 6 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for TriSalus Life Sciences and 1 mentions for Sight Sciences. TriSalus Life Sciences' average media sentiment score of 1.75 beat Sight Sciences' score of 0.23 indicating that Sight Sciences is being referred to more favorably in the media.
Summary
TriSalus Life Sciences beats Sight Sciences on 8 of the 15 factors compared between the two stocks.
Get TriSalus Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TriSalus Life Sciences Competitors List
Related Companies and Tools
